Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

tion; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of Specifid for use in clinical trials and, if Specifid receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using Specifid; potential delays in patient enrollment; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

FAVRILLE, INC.

(a development stage company)

BALANCE SHEETS

(in thousands, except share and per share data)

March 31, December 31,

2008 2007

(unaudited)

Assets

Current assets:

Cash and cash equivalents $ 16,089 $ 26,362

Short-term investments 3,569 3,577

Other current assets 1,007 806

Total current assets 20,665 30,745

Property and equipment, net 32,276
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, ... it has received the second $1.0M tranche under ... Research (SBIR) grant valued at up to $3.0 ... aerosolized KL4 surfactant as a potential medical countermeasure ...  Discovery Labs was awarded an initial $1.0 million ...
(Date:7/29/2015)... BANGALORE , July 30, 2015 ... Cell Market - Growth, Trends & Forecasts (2015-2020), , published ... worth US$ 30.25 billion by the end of 2020, with ... globally accounting for more than 40% of the global market ... grow at a CAGR of 13.7% during the period of ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... , NATICK, Mass., Sept. 14 Boston ... that it has entered into a co-marketing agreement with ... testing solutions for urinary incontinence. Bladder Health Network ... supplies and results analysis, helping to ensure that physicians ...
... 14 Health Robotics today reported,that Dr M Group has ... of its I.V. Compounding Centers in Malaysia,Singapore, Indonesia, Vietnam, and ... on 2 companies in the field of I.V.,Robotics, the doubts ... announced multi-year delays in bringing their robot to first,hospital,s use], ...
... , , , ... announced that the results of a comprehensive review of safety data from ... Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, ... risk-benefit profile of pirfenidone in IPF patients, a comprehensive review of safety ...
Cached Biology Technology:Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 2Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 3Dr M Group Selects Health Robotics' Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 2Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 3Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 4Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 5Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 6Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 7Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting 8
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... The microscopic phytoplankton Aureococcus anophagefferens , which causes ... to be a fierce competitor. In the first ... found that Aureococcus , unique gene complement allows ... human-modified ecosystems, which could help explain the global increases ...
... pathways that are mutated in many forms of cancer, ... disease including hypertrophic cardiomyopathy (HCM), a thickening of ... sudden death in children and young adults , have ... in the lab. In two separate but ...
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
Cached Biology News:First harmful algal bloom species genome sequenced 2First harmful algal bloom species genome sequenced 3Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4
pH-insensitive fluorescence (pH 2-12)...
HOXC11 Antibody...
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Biology Products: